(Total Views: 394)
Posted On: 01/23/2018 9:33:24 PM
Post# of 11803
J&J put out 4Q earnings today as a prelude to their 10K coming in about 30 days. Another bad quarter for the diabetes division. Domestic diabetes sales = terrible. International diabetes division = flat to slightly cratering. That sucking sound you hear is the American diabetes division going down the drain.
Diabetes Care
$390MM
(15.6%) Decrease in Gross Profit
(18.7%) Decrease in Operational Profit
J&J down $6.31 today. Not a peep on their message boards.
BGM (Blood Glucose Monitoring) price declines in the U.S. and category and share softness in EMEA coupled with insulin pump discontinuation in U.S. and Canada
DECN is a small struggling company with unparalled potential but an absolutely terrible shareholder base, not unlike many small public companies. Bad shareholders outnumber good shareholders by 5-6 to 1. Non-shareholders who are trying to destroy the company are in numbers approx. equal to good shareholders. DECN receives more trouble from its own shareholders than it does from J&J.
All IMO bashers.
Diabetes Care
$390MM
(15.6%) Decrease in Gross Profit
(18.7%) Decrease in Operational Profit
J&J down $6.31 today. Not a peep on their message boards.
BGM (Blood Glucose Monitoring) price declines in the U.S. and category and share softness in EMEA coupled with insulin pump discontinuation in U.S. and Canada
DECN is a small struggling company with unparalled potential but an absolutely terrible shareholder base, not unlike many small public companies. Bad shareholders outnumber good shareholders by 5-6 to 1. Non-shareholders who are trying to destroy the company are in numbers approx. equal to good shareholders. DECN receives more trouble from its own shareholders than it does from J&J.
All IMO bashers.
(1)
(1)
